News register
Search section
Search area
News Type
News type
Search date
Search word OR
List of related articles
Contents of related articles
No info was found
List of related articles
Contents of related articles
No info was found
View details
Information

10/12/2020 HYU News > Academics

Title

Professor Lee Dong-yoon obtains a patent on cell encapsulation of xenotransplantation jointly developed with Optipharm

Effects such as increasing the durability and survival rate of transplanted pancreatic cells and preventing them from easily decomposing in the body is expected

Global News Team

Copy URL / Share SNS

http://www.hanyang.ac.kr/surl/88IeB

Contents
Optipharm announced on the 17th that a patent related to the cell encapsulation of xenotransplantation, jointly developed by Lee Dong-yoon, a professor in the department of Bio-Engineering at Hanyang University, and Optipharm, has been obtained. The name of the patent is "Alignite microcapsule for cell membranes and its manufacturing method."

This patent is a technology that reduces side effects after the procedure, such as human immunization and hypoxia, by double-capping with substances called alginate and epigallocatechin gallate (EGCG) when implanting pancreatic cells of mini pigs into the human body.

Alginate is a polymeric compound available for human bodies approved by the Food and Drug Administration (FDA) and is a representative material used for cell screening. It is responsible for protecting pancreatic cells from human immunity. The pancreas does not affect the cell's original function as it can absorb the oxygen and nutrients needed for cell growth and secrete insulin. However, the fact that it melts in the body over time has been pointed out as a problem. 

To solve this problem, the patent included a process of coating called EGCG to the alginate that is wrapped in pancreatic cells. This will increase the durability and survival rate of transplanted pancreatic cells and prevent them from easily decomposing in the body. 

Optipharm's director, Choi Ki-myung, explained, "If you double-coat with EGCG made up of alginate and human-friendly natural substances, many problems such as fibrosis, shorter survival time, and excessive use of immunosuppressive agents can be solved."

Optipharm has been focusing on the cross-fertilization business for type 1 diabetes treatment by using the pancreatic cells of transgenic pigs, which are made by inserting or subtracting certain genes. The company plans to conduct a nonclinical experiment on monkeys next year in focus to stabilize the patented technology. 


Global News Team
global@hanyang.ac.kr
Translation by: Lee Hee-jin
Copy URL / Share SNS

0 Comments